Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.

Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT.

Chem Res Toxicol. 2018 Dec 17;31(12):1293-1304. doi: 10.1021/acs.chemrestox.8b00170. Epub 2018 Nov 19.

PMID:
30381944
2.

New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?

Dall'Era MA, De Vere White RW.

Eur Urol. 2018 Nov;74(5):549-550. doi: 10.1016/j.eururo.2018.08.014. Epub 2018 Sep 1. No abstract available.

PMID:
30177292
3.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

4.

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.

Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG.

FASEB J. 2018 Mar;32(3):1537-1549. doi: 10.1096/fj.201700740R. Epub 2018 Jan 3.

5.

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.

Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A.

Sci Rep. 2017 Sep 25;7(1):12277. doi: 10.1038/s41598-017-12543-9.

6.

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT.

Int J Cancer. 2017 Aug 1;141(3):604-613. doi: 10.1002/ijc.30747. Epub 2017 May 15.

7.

Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.

de Vere White R.

Eur Urol. 2017 Apr;71(4):688. doi: 10.1016/j.eururo.2016.12.017. Epub 2017 Jan 7. No abstract available.

PMID:
28073601
8.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00065. Epub 2017 Nov 2.

9.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

10.

Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

Chem Res Toxicol. 2016 Nov 21;29(11):1843-1848. Epub 2016 Oct 10.

11.

Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.

Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

PLoS One. 2016 Jan 22;11(1):e0146256. doi: 10.1371/journal.pone.0146256. eCollection 2016.

12.

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW.

PLoS One. 2015 Aug 13;10(8):e0134346. doi: 10.1371/journal.pone.0134346. eCollection 2015.

13.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET.

Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.

14.

The role of microRNA in castration-resistant prostate cancer.

Thieu W, Tilki D, de Vere White R, Evans CP.

Urol Oncol. 2014 Jul;32(5):517-523. doi: 10.1016/j.urolonc.2013.11.004. Review.

16.

Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.

Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN Jr, de Vere White R, Lam KS, Pan CX.

Int J Nanomedicine. 2012;7:2793-804. doi: 10.2147/IJN.S27734. Epub 2012 Jun 6.

17.

Human ESC self-renewal promoting microRNAs induce epithelial-mesenchymal transition in hepatocytes by controlling the PTEN and TGFβ tumor suppressor signaling pathways.

Jung CJ, Iyengar S, Blahnik KR, Jiang JX, Tahimic C, Torok NJ, de vere White RW, Farnham PJ, Zern M.

Mol Cancer Res. 2012 Jul;10(7):979-91. doi: 10.1158/1541-7786.MCR-11-0421. Epub 2012 May 23.

18.

Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW.

Horm Cancer. 2011 Aug;2(4):224-38. doi: 10.1007/s12672-011-0076-4.

19.

MicroRNA in prostate, bladder, and kidney cancer: a systematic review.

Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T.

Eur Urol. 2011 May;59(5):671-81. doi: 10.1016/j.eururo.2011.01.044. Epub 2011 Feb 1. Review.

PMID:
21296484
20.

Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.

Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO Jr, de Vere White R, Pan CX.

Mol Cancer. 2011 Jan 27;10(1):9. doi: 10.1186/1476-4598-10-9.

21.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

22.

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).

Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM.

BJU Int. 2011 Sep;108(5):693-9. doi: 10.1111/j.1464-410X.2010.09900.x. Epub 2010 Nov 24.

23.

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN Jr, Turteltaub K, Henderson P, Pan CX.

Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28.

24.

Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.

Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX.

Urol Oncol. 2012 Sep;30(5):635-45. doi: 10.1016/j.urolonc.2010.06.011. Epub 2010 Oct 2.

25.

The dogmas of nutrition and cancer: time for a second (and maybe third) look.

de Vere White R, Hackman RM, Kugelmass J.

Ann N Y Acad Sci. 2010 Mar;1190:118-25. doi: 10.1111/j.1749-6632.2009.05271.x.

PMID:
20388142
26.

Words of wisdom. Re: comparative effectiveness of minimally invasive vs open radical prostatectomy.

de Vere White R.

Eur Urol. 2010 Feb;57(2):355-6. doi: 10.1016/j.eururo.2009.11.017. No abstract available.

PMID:
20116768
27.

Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM.

Clin Cancer Res. 2009 Feb 1;15(3):788-96. doi: 10.1158/1078-0432.CCR-08-1402.

28.

Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines.

de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, Miyamoto S, de Vere White R, Lam KS, Lebrilla C.

Dis Markers. 2008;25(4-5):243-58.

29.

Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data.

Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM.

Bioinformatics. 2009 Jan 15;25(2):251-7. doi: 10.1093/bioinformatics/btn610. Epub 2008 Dec 9.

30.

Re: defining optimal therapy for muscle-invasive bladder cancer.

de Vere White R.

Eur Urol. 2008 Jun;53(6):1295-6. doi: 10.1016/j.eururo.2008.03.020. No abstract available.

PMID:
18471557
31.

Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.

Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT.

Chem Res Toxicol. 2007 Dec;20(12):1745-51. Epub 2007 Nov 15.

PMID:
18001055
32.

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.

Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN Jr, de Vere White RW.

Clin Cancer Res. 2007 Oct 15;13(20):6204-16.

33.

Finasteride for chemoprevention of prostate cancer: why has it not been embraced?

de Vere White RW.

J Clin Oncol. 2007 Jul 20;25(21):2999-3000. No abstract available.

PMID:
17634478
34.

GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.

Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.

Prostate. 2007 Apr 1;67(5):521-35.

PMID:
17252539
35.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.

Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED.

Oncol Rep. 2006 Oct;16(4):807-10.

PMID:
16969498
36.

Accrual issues in genitourinary cancer clinical trials.

Lara PN Jr, de Vere White R.

Urol Oncol. 2006 Sep-Oct;24(5):379-83. No abstract available.

PMID:
16962485
37.

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ.

Int J Oncol. 2006 Jul;29(1):49-55.

PMID:
16773184
38.

Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.

Hah SS, Stivers KM, de Vere White RW, Henderson PT.

Chem Res Toxicol. 2006 May;19(5):622-6.

PMID:
16696564
39.

The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.

Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW.

Oncogene. 2006 Mar 30;25(14):2082-93.

PMID:
16434975
40.

Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.

You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH.

Cancer Res. 2006 Jan 1;66(1):175-83.

41.

The androgen receptor and mechanisms for androgen independence in prostate cancer.

Javidan J, Deitch AD, Shi XB, de Vere White RW.

Cancer Invest. 2005;23(6):520-8. Review. No abstract available.

PMID:
16203660
42.

Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.

Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE.

Cancer Res. 2005 Jan 1;65(1):54-65.

43.
44.

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion.

Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C.

BJU Int. 2004 Jan;93(1):143-50.

45.
46.

Functional analysis of 44 mutant androgen receptors from human prostate cancer.

Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW.

Cancer Res. 2002 Mar 1;62(5):1496-502.

47.

Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.

Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, LaSalle JM.

Cancer J. 2001 Sep-Oct;7(5):395-403.

PMID:
11693898
48.

Present and future management of prostate cancer.

de Vere White R.

Cancer Biother Radiopharm. 2000 Apr;15(2):121-5. No abstract available.

PMID:
10803316
49.
50.

Predicting prognosis in patients with superficial bladder cancer.

de Vere White RW, Stapp E.

Oncology (Williston Park). 1998 Dec;12(12):1717-23; discussion 1724-6. Review.

Supplemental Content

Loading ...
Support Center